Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26127200 | 0.85 | LMNA (0.54) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL26130734 | 0.79 | LMNA (0.48) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL7966541 | 0.79 | LMNA (0.48) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL31270697 | 0.79 | LMNA (0.74) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL17102309 | 0.78 | LMNA (0.64) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL31729500 | 0.74 | LMNA (0.68) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL169675 | 0.74 | LMNA (0.68) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL23121198 | 0.74 | LMNA (0.68) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL29700587 | 0.74 | LMNA (0.68) | LMNAL3MBTL1KCNH2HTR1AHTR2C | |
| SCHEMBL29700592 | 0.73 | KCNH2 (0.44) | LMNAL3MBTL1KCNH2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028333-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| US-12435072-B2 | Compounds | VICORE PHARMA AB (SE) | 2025-10-07 | — | — | US | disclosed |
| US-20240174657-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2024-05-30 | — | — | US | disclosed |
| EP-4313976-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Vicore Pharma AB (SE) | 2024-02-07 | — | — | EP | disclosed |
| US-20220388994-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2022-12-08 | — | — | US | disclosed |
| WO-2022200786-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2022-09-29 | — | — | WO | disclosed |
| EP-4031240-A1 | NEW COMPOUNDS | Vicore Pharma AB (SE) | 2022-07-27 | — | — | EP | disclosed |
| CN-114786774-A | Novel compounds | 维科尔药物公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021053344-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2021-03-25 | — | — | WO | disclosed |
| US-6333335-B1 | TO INHIBIT PRENYL-PROTEIN TRANSFERASE AND THE PRENYLATION OF THE ONCOGENE PROTEIN RAS | MERCK & CO., INC. | 2001-12-25 | — | — | US | disclosed |
| WO-2001007046-A1 | PRENYL-PROTEIN TRANSFERASE INHIBITORS | MERCK & CO., INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028333-A1 | NEW COMPOUNDS | AGTR1, AGTR2, REN | LMNA 1958/4885L3MBTL1 4556/4885KCNH2 1389/4885 |
| US-20220388994-A1 | NEW COMPOUNDS | RXFP3, RXFP4, RXFP1 | LMNA 3099/4885L3MBTL1 3046/4885KCNH2 1563/4885 |
| US-20240174657-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | AGTR1, AGTR2, MSR1 | LMNA 3605/4885L3MBTL1 4509/4885KCNH2 1188/4885 |
| US-12435072-B2 | Compounds | RXFP3, RXFP4, ARG1 | LMNA 2591/4885L3MBTL1 2822/4885KCNH2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.